阿伐苏单抗 T76858

Product Introduction
Bioactivity


英文名: Ascrinvacumab

描述: Ascrinvacumab (PF-03446962) 是一种针对 ALK-1 的高效人源化 IgG2 单克隆抗体。Ascrinvacumab 对人 ALK1 的 Kd 值为 7 nM。Ascrinvacumab 对 TGF-β 有抑制作用，可用于研究肝细胞癌 (HCC)。

体外活性: Ascrinvacumab binds to human ALK1 with a Kd value of 7 nM[1].In a 30-minute treatment, Ascrinvacumab blocks the response induced by BMP9 and FCS, alleviating BMP9-induced Smad1 phosphorylation intensity and duration[1].At concentrations ranging from 0.01 to 10 μg/mL for 2 hours, Ascrinvacumab inhibits the binding of BMP9 to ALK1[1].At 40 μg/mL for 2 hours, Ascrinvacumab effectively inhibits endothelial sprouting in human umbilical vein endothelial cells (HUVECs)[1].

体内活性: In a mouse xenograft tumor model, the combination of Ascrinvacumab with bevacizumab (anti-VEGF) reduces human vascular density and enhances the anti-tumor efficacy[1].

存储条件: store at low temperaturestore at -80°C

关键字: PF 03446962 | PF03446962 | Ascrinvacumab

相关产品: TGFBR1-IN-1 | CH5424802 analog | SB 525334 | Ceritinib | 6-Demethoxytangeretin | Entrectinib | ALK-IN-5 | (-)-Cevimeline hydrochloride hemihydrate | AZ12601011 | N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-bromoaniline

阿伐苏单抗 T76858信息由TargetMol中国为您提供，如您想了解更多关于阿伐苏单抗 T76858报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途